journal article·2026-05Open access

IL‐3 Modulates Microglia Polarization and Attenuates Neuroinflammation in Traumatic Brain Injury

Nana Huang, Qingchen Zhang, Yanrui Chen, Dapeng Yu, Ronghan Liu, Jianning Kang, Xiang Fang, Ying Zhang, Hong Bian, Yanxin Zhao, Yongcheng Yin, Ce Zhang, Yanfei Jia, Qingfa Chen, Yuepeng Fang, Shang Li, Fang Li, Zhengxin Jin, Bin Ning

Advanced Science· Volume 13· Issue 29

Abstract

ABSTRACT Microglia play a crucial role in the progression of neuroinflammation following traumatic brain injury (TBI). Interleukin‐3 (IL‐3), a significant regulatory factor, has been involved in the pathogenesis of various diseases, yet its effects on neuroinflammation post‐TBI through microglia remain unclear. Here, we evaluate the potential of IL‐3 to alleviate neuroinflammation in microglia following TBI. Using the ABplex Multi‐Metric Streaming Joint Analysis to detect inflammatory factors, we observed significantly elevated levels of IL‐3 in cerebrospinal fluid, but not in blood samples, of patients with headaches and TBI. In addition, we found that administration of exogenous IL‐3 within the brain reduced neuroinflammation and promoted functional recovery in rat TBI models. Mechanistically, we identified Peroxiredoxin‐1 (PRDX1) as the target of IL‐3 in microglia. Notably, the protective effects of IL‐3 in TBI rats were abolished when PRDX1 was specifically knocked down in microglia. In conclusion, our experimental research demonstrates that IL‐3 acts as a key modulator via regulating microglia polarization to inhibit neuroinflammation. IL‐3 improves neurological function and prognosis in TBI rats by recruiting PRDX1 through IL‐3R to modulate microglia polarization. Therefore, IL‐3 may represent a novel therapeutic strategy for TBI.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Neuroinflammation and Neurodegeneration Mechanisms · Traumatic Brain Injury and Neurovascular Disturbances · S100 Proteins and Annexins

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Central Hospital Affiliated to Shandong First Medical University Shandong First Medical University & Shandong Academy of Medical Sciences Jinan China

Jinan Central Hospital Shandong University Jinan China

School of Pharmacy Shandong University of Traditional Chinese Medicine Jinan China

Funding

Natural Science Foundation of Shandong Province · Taishan Scholar Foundation of Shandong Province

References (82)

Show source-provided references
1. 10.3389/fncel.2019.0052810.3389/fncel.2019.00528 ↗
2. 10.1016/S1474-4422(18)30468-X10.1016/S1474-4422(18)30468-X ↗
3. 10.1089/neu.2009.120610.1089/neu.2009.1206 ↗
4. 10.1016/S1474-4422(18)30469-110.1016/S1474-4422(18)30469-1 ↗
5. 10.1097/00001199-200307000-0000310.1097/00001199-200307000-00003 ↗
6. 10.1097/TA.000000000000185210.1097/TA.0000000000001852 ↗
7. 10.1016/j.nurt.2009.10.02310.1016/j.nurt.2009.10.023 ↗
8. 10.1186/s12974-017-0934-210.1186/s12974-017-0934-2 ↗
9. 10.1038/nrneurol.2017.11610.1038/nrneurol.2017.116 ↗
10. 10.1016/S0140-6736(04)17188-210.1016/S0140-6736(04)17188-2 ↗
11. 10.1038/s41392-023-01588-010.1038/s41392-023-01588-0 ↗
12. 10.1002/advs.20230018010.1002/advs.202300180 ↗
13. Retinal Microenvironment‐Protected Rhein‐Gffye Nanofibers Attenuate Retinal Ischemia‐Reperfusion Injury via Inhibiting Oxidative stress And Regulating Microglial/Macrophage m1/m2 Polarization
14. 10.1038/s41583-023-00709-610.1038/s41583-023-00709-6 ↗
15. 10.1186/1742-2094-2-2410.1186/1742-2094-2-24 ↗
16. 10.1016/j.arr.2023.10216010.1016/j.arr.2023.102160 ↗
17. 10.1016/j.expneurol.2015.08.01810.1016/j.expneurol.2015.08.018 ↗
18. 10.2174/187152731966620091814590310.2174/1871527319666200918145903 ↗
19. 10.2174/15665240150915110513062810.2174/156652401509151105130628 ↗
20. 10.1016/j.tem.2021.12.00510.1016/j.tem.2021.12.005 ↗
21. 10.1007/s10753-019-01152-510.1007/s10753-019-01152-5 ↗
22. 10.4103/1673-5374.28695410.4103/1673-5374.286954 ↗
23. 10.1016/j.jconrel.2020.04.03610.1016/j.jconrel.2020.04.036 ↗
24. 10.1186/s12974-020-02041-710.1186/s12974-020-02041-7 ↗
25. 10.1172/jci.insight.13365210.1172/jci.insight.133652 ↗
26. 10.1038/s41586-021-03734-610.1038/s41586-021-03734-6 ↗
27. 10.1016/j.immuni.2019.03.02210.1016/j.immuni.2019.03.022 ↗
28. 10.1161/ATVBAHA.119.31199410.1161/ATVBAHA.119.311994 ↗
29. 10.1016/j.immuni.2023.04.01310.1016/j.immuni.2023.04.013 ↗
30. 10.1111/all.1348010.1111/all.13480 ↗
31. 10.1006/jaut.1997.014210.1006/jaut.1997.0142 ↗
32. 10.4049/jimmunol.100269110.4049/jimmunol.1002691 ↗
33. 10.1016/j.immuni.2023.06.00910.1016/j.immuni.2023.06.009 ↗
34. 10.1016/j.expneurol.2011.04.00610.1016/j.expneurol.2011.04.006 ↗
35. 10.1097/CCM.000000000000293810.1097/CCM.0000000000002938 ↗
36. 10.3109/02699052.2015.106534410.3109/02699052.2015.1065344 ↗
37. 10.1038/s41392-022-01231-410.1038/s41392-022-01231-4 ↗
38. 10.1038/s41419-023-05732-010.1038/s41419-023-05732-0 ↗
39. 10.1161/CIRCRESAHA.121.31886610.1161/CIRCRESAHA.121.318866 ↗
40. 10.1016/j.redox.2022.10234710.1016/j.redox.2022.102347 ↗
41. 10.1016/j.kint.2023.04.01310.1016/j.kint.2023.04.013 ↗
42. 10.1016/j.cell.2009.06.04210.1016/j.cell.2009.06.042 ↗
43. 10.1038/nature0181910.1038/nature01819 ↗
44. 10.3390/antiox912120310.3390/antiox9121203 ↗
45. 10.1016/j.molmed.2019.09.00710.1016/j.molmed.2019.09.007 ↗
46. 10.1016/j.redox.2018.11.01710.1016/j.redox.2018.11.017 ↗
47. 10.1016/j.biopha.2020.11035710.1016/j.biopha.2020.110357 ↗
48. 10.4049/jimmunol.179.11.784010.4049/jimmunol.179.11.7840 ↗
49. 10.1007/s10787-022-01017-810.1007/s10787-022-01017-8 ↗
50. 10.1186/s12964-022-00862-y10.1186/s12964-022-00862-y ↗
51. 10.1186/s12974-022-02633-510.1186/s12974-022-02633-5 ↗
52. 10.1016/j.intimp.2022.10890210.1016/j.intimp.2022.108902 ↗
53. 10.1038/s41590-022-01208-z10.1038/s41590-022-01208-z ↗
54. 10.1523/JNEUROSCI.2469-20.202010.1523/JNEUROSCI.2469-20.2020 ↗
55. 10.1186/s12974-022-02608-610.1186/s12974-022-02608-6 ↗
56. 10.1016/j.tins.2023.08.00810.1016/j.tins.2023.08.008 ↗
57. Il‐3 Receptor Signalling Suppresses Chronic Intestinal Inflammation by Controlling Mechanobiology and Tissue Egress of Regulatory T Cells
58. 10.1016/j.bbi.2012.06.00810.1016/j.bbi.2012.06.008 ↗
59. 10.1016/j.bbrc.2019.08.07710.1016/j.bbrc.2019.08.077 ↗
60. 10.1016/j.canlet.2009.04.04310.1016/j.canlet.2009.04.043 ↗
61. 10.1096/fj.201801150R10.1096/fj.201801150R ↗
62. 10.3389/fnins.2020.0018110.3389/fnins.2020.00181 ↗
63. 10.1038/srep3830010.1038/srep38300 ↗
64. 10.1016/j.redox.2019.10134210.1016/j.redox.2019.101342 ↗
65. 10.3390/nu1302031110.3390/nu13020311 ↗
66. 10.1016/j.intimp.2023.10981310.1016/j.intimp.2023.109813 ↗
67. 10.1155/2021/145708910.1155/2021/1457089 ↗
68. 10.1016/j.freeradbiomed.2004.02.07510.1016/j.freeradbiomed.2004.02.075 ↗
69. 10.1016/j.freeradbiomed.2020.11.01910.1016/j.freeradbiomed.2020.11.019 ↗
70. 10.1007/s10571-015-0167-910.1007/s10571-015-0167-9 ↗
71. 10.4049/jimmunol.181.1.68010.4049/jimmunol.181.1.680 ↗
72. 10.1016/S0140-6736(74)91639-010.1016/S0140-6736(74)91639-0 ↗
73. 10.1161/01.STR.19.12.149710.1161/01.STR.19.12.1497 ↗
74. The ARRIVE Guidelines 2.0: Updated Guidelines for Reporting ANIMAL Research
75. 10.1038/jcbfm.2012.11410.1038/jcbfm.2012.114 ↗
76. 10.1159/00048705610.1159/000487056 ↗
77. 10.3390/nu1212375210.3390/nu12123752 ↗
78. 10.1007/978-1-4939-8994-2_1010.1007/978-1-4939-8994-2_10 ↗
79. 10.1161/hs1101.09836710.1161/hs1101.098367 ↗
80. 10.1006/meth.2001.126210.1006/meth.2001.1262 ↗
81. 10.1016/j.expneurol.2010.05.02010.1016/j.expneurol.2010.05.020 ↗
82. 10.1080/15548627.2018.153119610.1080/15548627.2018.1531196 ↗